Please assess the completion status of the following clinical trial:

Trial Title: Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous established diagnosis of Osteogenesis Imperfecta AND~* \> 2 previous adult fractures, AND/OR~* BMD at lumbar spine, femoral neck or total hip T score \< -2.0~Exclusion Criteria:~* Open epiphyses.~* History of external beam radiation to the skeleton.~* Pagets disease.~* Bone metastases or skeletal malignancies.~* Total lifetime exposure to any antiresorptive medication \< 90 days (Primary Inclusion).~* Treatment with any antiresorptive medication 12 months proceeding enrollment - (Secondary Inclusion).~* Women with OI who are pregnant or unwilling to use 1 form of contraception.~* Vitamin D insufficiency (25-hydroxyvitamin D \<15ng/ml)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (FORTEO) (Type: ACTIVE_COMPARATOR): Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
- Placebo (Type: PLACEBO_COMPARATOR): Daily SQ placebo for 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).